A detailed history of Ethic Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Ethic Inc. holds 6,114 shares of BMRN stock, worth $407,375. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,114
Previous 4,712 29.75%
Holding current value
$407,375
Previous $387,000 10.85%
% of portfolio
0.01%
Previous 0.01%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$69.02 - $93.84 $96,766 - $131,563
1,402 Added 29.75%
6,114 $429,000
Q2 2024

Aug 13, 2024

SELL
$74.43 - $92.22 $104,350 - $129,292
-1,402 Reduced 22.93%
4,712 $387,000
Q1 2024

May 13, 2024

BUY
$83.81 - $99.0 $99,063 - $117,018
1,182 Added 23.97%
6,114 $533,000
Q4 2023

Feb 14, 2024

SELL
$76.22 - $98.51 $77,820 - $100,578
-1,021 Reduced 17.15%
4,932 $475,000
Q3 2023

Nov 14, 2023

BUY
$85.07 - $94.48 $235,218 - $261,237
2,765 Added 86.73%
5,953 $526,000
Q2 2023

Aug 14, 2023

SELL
$86.68 - $100.3 $34,932 - $40,420
-403 Reduced 11.22%
3,188 $276,000
Q1 2023

May 12, 2023

BUY
$87.74 - $117.27 $43,431 - $58,048
495 Added 15.99%
3,591 $349,000
Q4 2022

Feb 14, 2023

BUY
$80.93 - $108.63 $250,559 - $336,318
3,096 New
3,096 $320,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Ethic Inc. Portfolio

Follow Ethic Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ethic Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ethic Inc. with notifications on news.